Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €5.34 EUR
Change Today +0.139 / 2.67%
Volume 0.0
PGP On Other Exchanges
As of 2:16 AM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/16/15 - €6.79
52 Week Low
05/9/14 - €2.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

progenics pharmaceuticals (PGP) Related Businessweek News

No Related Businessweek News Found

progenics pharmaceuticals (PGP) Details

Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. It also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. In addition, the company develops Relistor-oral that has completed Phase III testing for the treatment of OIC. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, as well as has collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

57 Employees
Last Reported Date: 03/16/15
Founded in 1986

progenics pharmaceuticals (PGP) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $535.6K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $279.6K
Executive Vice President of Medical Affairs
Total Annual Compensation: $426.5K
Senior Vice President of Manufacturing
Total Annual Compensation: $296.5K
Compensation as of Fiscal Year 2013.

progenics pharmaceuticals (PGP) Key Developments

Progenics Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Reports Impairment Charges for the Fourth Quarter of 2014

Progenics Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. The company reported Fourth quarter revenue resulted in a loss of $0.6 million, primarily from RELISTOR royalty losses due to Salix's plan to accelerate the reduction of wholesaler inventory levels and substantially cease all sales efforts to wholesalers in the fourth quarter of 2014. This compares to revenues of $3.0 million due to RELISTOR royalty income in the fourth quarter of 2013. Operating loss was $12,954,000 against $8,923,000 a year ago. Net loss before income tax benefit was $12,940,000 against $8,913,000 a year ago. Net loss was $12,179,000 or $0.18 per basic and diluted share against $8,551,000 or $0.14 per basic and diluted share a year ago. For the year, the company reported total revenue of $44,377,000 against $7,862,000 a year ago. Operating income was $3,370,000 against operating loss of $42,980,000 a year ago. Net income before income tax benefit was $3,421,000 against net loss before income tax benefit of $42,934,000 a year ago. Net income was $4,410,000 or $0.06 per basic and diluted share against net loss of $42,572,000 or $0.76 per basic and diluted share a year ago. Full year 2014 revenue was up from the prior year, reflecting an increase in collaboration revenue, primarily resulting from the recognition of milestone from Salix, partially offset by decrease in RELISTOR royalty income, compared to 2013. For the quarter, the company reported intangible impairment charges of $2,100,000.

Progenics Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 16, 2015

Progenics Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 16, 2015

Progenics Pharmaceuticals Presents Positive Phase 2 Data for PSMA

Progenics Pharmaceuticals, Inc. announced full results from its Phase 2 clinical study of PSMA ADC in patients with metastatic castration-resistant prostate cancer (mCRPC), including new data from the recently completed chemo-na ve cohort. The data was presented in a poster session and was also selected for inclusion in the ASCO GU Audio Poster Tour at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, taking place from February 26 28, 2015 in Orlando, Florida. The Phase 2 trial assessed the anti-tumor activity and tolerability of PSMA ADC, an antibody drug conjugate, in both taxane-experienced and chemo-na ve patients that had progressed following treatment with abiraterone and/or enzalutamide. In the chemo-na ve cohort, treatment with PSMA ADC reduced tumor size and levels of PSA and CTCs (circulating tumor cells) evidencing strong anti-tumor activity. Among these chemo-na ve patients, one (3%) had a complete radiological response, four (14%) had a partial radiological response, 22 (76%) showed stable disease, and two (7%) experienced progressive disease. The study enrolled 119 patients with mCRPC that had progressed following treatment with abiraterone and/or enzalutamide, including 84 taxane-experienced patients and 35 chemo-na ve patients. Patients in the trial received PSMA ADC 2.5mg/kg or 2.3 mg/kg intravenously three times weekly for up to 8 cycles. Safety, antitumor activity, and exploratory biomarkers were assessed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGP:GR €5.34 EUR +0.139

PGP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $13.44 USD +0.29
CTI BioPharma Corp $1.87 USD +0.06
Inovio Pharmaceuticals Inc $8.33 USD +0.045
Peregrine Pharmaceuticals Inc $1.38 USD -0.005
Rigel Pharmaceuticals Inc $3.35 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation PGP Industry Range
Price/Earnings 89.6x
Price/Sales 9.1x
Price/Book 3.2x
Price/Cash Flow 81.4x
TEV/Sales 6.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at